Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accumulated Expenses (2023 - 2025)

CG Oncology filings provide 3 years of Accumulated Expenses readings, the most recent being $24.2 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 65.07% to $24.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.2 million, a 65.07% increase, with the full-year FY2025 number at $24.2 million, up 65.07% from a year prior.
  • Accumulated Expenses hit $24.2 million in Q4 2025 for CG Oncology, up from $20.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $24.2 million in Q4 2025 to a low of $5.1 million in Q1 2024.
  • Median Accumulated Expenses over the past 3 years was $14.7 million (2024), compared with a mean of $14.7 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 40.43% in 2024 and later soared 222.36% in 2025.
  • CG Oncology's Accumulated Expenses stood at $10.4 million in 2023, then skyrocketed by 40.43% to $14.7 million in 2024, then soared by 65.07% to $24.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $24.2 million (Q4 2025), $20.4 million (Q3 2025), and $23.0 million (Q2 2025) per Business Quant data.